Hepatic insulin resistance represents a paradox in hepatic steatosis since insulin receptor activation of insulin receptor substrate-1 (IRS-1) is active and accounts for increased DNL, yet insulin does not inhibit insulin receptor substrate-2, which controls liver gluconeogenesis [63]. The gene discussed is IRS1; the disease is Hepatic steatosis.